241 related articles for article (PubMed ID: 34014535)
21. Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma.
Bai RL; Wang NY; Zhao LL; Zhang YF; Cui JW
Hepatobiliary Pancreat Dis Int; 2022 Feb; 21(1):10-24. PubMed ID: 34538570
[TBL] [Abstract][Full Text] [Related]
22. Pathology and molecular genetics of pancreatic neoplasms.
Wood LD; Hruban RH
Cancer J; 2012; 18(6):492-501. PubMed ID: 23187835
[TBL] [Abstract][Full Text] [Related]
23. Genetics and biology of pancreatic ductal adenocarcinoma.
Ying H; Dey P; Yao W; Kimmelman AC; Draetta GF; Maitra A; DePinho RA
Genes Dev; 2016 Feb; 30(4):355-85. PubMed ID: 26883357
[TBL] [Abstract][Full Text] [Related]
24. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies.
Osei-Bordom DC; Serifis N; Brown ZJ; Hewitt DB; Lawal G; Sachdeva G; Cloonan DJ; Pawlik TM
Surg Oncol; 2022 Aug; 43():101803. PubMed ID: 35830772
[TBL] [Abstract][Full Text] [Related]
25. Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.
Huang J; Löhr JM; Nilsson M; Segersvärd R; Matsson H; Verbeke C; Heuchel R; Kere J; Iafrate AJ; Zheng Z; Ye W
Clin Chem; 2015 Nov; 61(11):1408-16. PubMed ID: 26378065
[TBL] [Abstract][Full Text] [Related]
26. Short report - Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):1017-1019. PubMed ID: 35179767
[TBL] [Abstract][Full Text] [Related]
27. Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma.
Wu H; Tian W; Tai X; Li X; Li Z; Shui J; Yu J; Wang Z; Zhu X
BMC Genomics; 2021 Nov; 22(1):833. PubMed ID: 34789165
[TBL] [Abstract][Full Text] [Related]
28. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
29. Genetic progression of pancreatic cancer.
Cowan RW; Maitra A
Cancer J; 2014; 20(1):80-4. PubMed ID: 24445769
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
31. Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stages.
Zhang X; Feng S; Wang Q; Huang H; Chen R; Xie Q; Zhang W; Wang A; Zhang S; Wang L; Yao M; Ling Q
J Cell Mol Med; 2021 Feb; 25(3):1750-1758. PubMed ID: 33452856
[TBL] [Abstract][Full Text] [Related]
32. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
[TBL] [Abstract][Full Text] [Related]
33. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
34. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract][Full Text] [Related]
35. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
[TBL] [Abstract][Full Text] [Related]
37. Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.
Andersen HB; Ialchina R; Pedersen SF; Czaplinska D
Cancer Metastasis Rev; 2021 Dec; 40(4):1093-1114. PubMed ID: 34855109
[TBL] [Abstract][Full Text] [Related]
38. Highlights on the Role of
Hafezi S; Saber-Ayad M; Abdel-Rahman WM
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638560
[TBL] [Abstract][Full Text] [Related]
39. NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
Ramakrishnan G; Parajuli P; Singh P; Friend C; Hurwitz E; Prunier C; Razzaque MS; Xu K; Atfi A
Cell Rep; 2022 Nov; 41(6):111623. PubMed ID: 36351408
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
Zhou L; Zhang WG; Wang DS; Tao KS; Song WJ; Dou KF
Oncol Rep; 2014 Oct; 32(4):1734-40. PubMed ID: 25109303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
